Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelm May 3, 2022 Auto Bot Aduhelm (Drug), alzheimer's disease, Appointments and Executive Changes, Biogen Inc, European Union, Food and Drug Administration, Medicare, Vounatsos, Michel 0 The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefit and serious safety risks.